Pharmaceuticals
Modern Chinese Medicine Group Co., Ltd. announces its subscription results
HONG KONG, Jan. 14, 2021 /PRNewswire/ -- Modern Chinese Medicine Group Co., Ltd. ("Modern Chinese Medicine", together with its subsidiaries, the "Group"; stock code: 1643), which principally engages in the production of proprietary Chinese medicine (the "PCM") and offers both over-the-counter (the...
2021-01-14 14:30
10128
Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, presented at the J.P. Morgan 39th Annual Hea...
2021-01-14 09:32
2620
ATIF Holdings Limited Announces Its IPO Client Soars 100% in the U.S. Trading Debut
LOS ANGELES, Jan. 13, 2021 /PRNewswire/ -- ATIF Holdings Limited (Nasdaq: ATIF, "ATIF"), a company providing business consulting and media services in Asia and North America, announces the client ofATIF, a China-based pharmaceutical and chemical products manufacturer, Qilian International Holding...
2021-01-13 21:00
9844
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval fo...
2021-01-13 21:00
1544
Hanmi presents solution package for coping with COVID-19, including the mass production of nucleic acid vaccines (DNA/mRNA vaccine)
SEOUL, South Korea, Jan. 13, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd., announced "endless challenges and new commitments for the pharmaceutical industry" as their management slogan for the new year, presenting the business direction for the year 2021 at the 39th JP Morgan Healthcare...
2021-01-13 09:00
2452
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)
SAN FRANCISCO and SUZHOU, China, Jan. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-01-13 08:00
6028
Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced thatFrederick Beddingfield, Chief Executive Officer of Kira Pharm...
2021-01-12 22:57
1915
Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer
STOCKHOLM, Jan. 12, 2021 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish drug discovery company, andUniversity of Dundee, a top-ranked university in the UK for biological sciences, today announced a new research collaboration agreement. The two parties will work together in a project aimed ...
2021-01-12 17:26
1108
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Details of Initial Therapeutic Programs to be Shared at the 39th J.P. Morgan Healthcare Conference BOSTON, Jan. 11, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changin...
2021-01-12 12:26
1758
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41
SHANGHAI, Jan. 11, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the positive phase I clinical results of ASC41 oral ...
2021-01-12 08:30
2330
MedSkin Solutions Dr. Suwelack AG Receives FDA 510(k) Clearance for MatriDerm® - Its Three-Dimensional Acellular Collagen Elastin Dermal Matrix Portfolio
MedSkin Solutions Dr. Suwelack AG announces receiving FDA 510(k) clearance for its flagship Med Care product portfolio MatriDerm®. HAMBURG, Germany, Jan. 12, 2021 /PRNewswire/ -- MatriDerm® is a single-use three-dimensional acellular dermal matrix composed of bovine collagen fibers and bovine el...
2021-01-12 04:38
1251
Regent Pacific Announces Key Research Findings On FORTACIN™
HONG KONG, Jan. 11, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce several key findings on the w...
2021-01-11 23:36
9535
Korea Fair Trade Commission Assigns Compliance Program Rating of "A" to Yuyu Pharma
SEOUL, South Korea, Jan. 11, 2021 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX: 000220) received Compliance Program (CP) Rating of "A" from the Korea Fair Trade Commission (FTC). Yuyu Pharma (Yuyu) established its CP team in 2016 with the help of the law firm Kim & Chang. The CP tea...
2021-01-11 22:00
4473
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the NMPA.
SHENZHEN, China, Jan. 11, 2021 /PRNewswire/ -- On January 8, 2021, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted its pivotal phase III clinical trial application (IND) of national class I innovative drug Chiauranib to NMPA, for the treatment...
2021-01-11 11:33
2454
Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference
SHANGHAI and SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology an...
2021-01-11 07:26
1741
Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients
SUZHOU, China, Jan. 10, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr.Andy Goren and Dr. Flávio Adsuara C...
2021-01-10 16:55
3202
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...
2021-01-09 11:06
5608
NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis
MILAN and HONG KONG, Jan. 8, 2021 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agr...
2021-01-08 20:55
5374
Gracell Biotechnologies Announces Pricing of Initial Public Offering
SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...
2021-01-08 14:55
9391
Atsushi Sugita Succeeds Koichi Takagi as President & CEO of Maruho
OSAKA, Japan, Jan. 8, 2021 /PRNewswire/ -- Maruho Co., Ltd. (hereinafter "Maruho"), based inOsaka, Japan, announced that its Board of Directors has named Atsushi Sugita Representative Director, President & CEO, effective December 18, 2020. Koichi Takagi has served as President & CEO since 1999 and...
2021-01-08 14:00
3821
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400